CMS quarterly HCPCS update
HCPCS Drug Code Changes: October 2026
The J-codes and Q-codes CMS added, discontinued or reworded in the latest quarterly HCPCS update, and every retired drug code still in the CMS file.
New codes
| Code | Descriptor | Effective |
|---|---|---|
| J0014 | Cocaine hydrochloride nasal solution (goprelto), 1 mg | Oct 1, 2026 |
| J0643 | Injection, leucovorin calcium, not otherwise specified, 1 mg | Oct 1, 2026 |
| J0644 | Injection, leucovorin calcium (avyxa), 1 mg | Oct 1, 2026 |
| J0871 | Injection, daptomycin (endo), not therapeutically equivalent to j0878, 1 mg | Oct 1, 2026 |
| J1757 | Injection, tividenofusp alfa-eknm, 1 mg | Oct 1, 2026 |
| J1818 | Injection, pegzilarginase-nbln, 0.05 mg | Oct 1, 2026 |
| J1946 | Injection, furosemide (lasix onyu), 1 mg | Oct 1, 2026 |
| J1947 | Injection, furosemide (furoscix), 1 mg | Oct 1, 2026 |
| J1957 | Injection, levetiracetam, 5 mg | Oct 1, 2026 |
| J1958 | Injection, levetiracetam in sodium chloride, 5 mg | Oct 1, 2026 |
| J3268 | Injection, delafloxacin, 1 mg | Oct 1, 2026 |
| J3406 | Injection, omidubicel-onlv, per therapeutic dose | Oct 1, 2026 |
| J7524 | Mycophenolate mofetil, oral, 5 mg | Oct 1, 2026 |
| J7526 | Injection, mycophenolate mofetil, 5 mg | Oct 1, 2026 |
| J7529 | Mycophenolate mofetil, for suspension, oral, 5 mg | Oct 1, 2026 |
| J7530 | Mycophenolate mofetil (myhibbin), oral suspension, 5 mg | Oct 1, 2026 |
| J7531 | Prednisolone sodium phosphate, orally disintegrating tablet, 1 mg | Oct 1, 2026 |
| J9066 | Injection, bendamustine hydrochloride (avyxa), 1 mg | Oct 1, 2026 |
| J9186 | Injection, etoposide (avyxa), 1 mg | Oct 1, 2026 |
| J9187 | Injection, etoposide, 1 mg | Oct 1, 2026 |
| J9191 | Injection, fluorouracil (avyxa), 10 mg | Oct 1, 2026 |
| J9192 | Injection, fluorouracil, 10 mg | Oct 1, 2026 |
| J9362 | Injection, trabectedin, 0.01 mg | Oct 1, 2026 |
| Q5172 | Injection, filgrastim-laha (filkri), biosimilar, 1 microgram | Oct 1, 2026 |
| Q5173 | Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg | Oct 1, 2026 |
Discontinued codes
Each code’s page lists the current codes for the same drug.
| Code | Descriptor | Last valid date |
|---|---|---|
| J0640 | Injection, leucovorin calcium, per 50 mg | Sep 30, 2026 |
| J1941 | Injection, furosemide (furoscix), 20 mg | Sep 30, 2026 |
| J1953 | Injection, levetiracetam, 10 mg | Sep 30, 2026 |
| J7514 | Mycophenolate mofetil (myhibbin), oral suspension, 100 mg | Sep 30, 2026 |
| J7517 | Mycophenolate mofetil, oral, 250 mg | Sep 30, 2026 |
| J7519 | Injection, mycophenolate mofetil, 10 mg | Sep 30, 2026 |
| J7528 | Mycophenolate mofetil, for suspension, oral, 100 mg | Sep 30, 2026 |
| J9181 | Injection, etoposide, 10 mg | Sep 30, 2026 |
| J9190 | Injection, fluorouracil, 500 mg | Sep 30, 2026 |
| J9352 | Injection, trabectedin, 0.1 mg | Sep 30, 2026 |
Descriptor changes
All retired drug codes
161 J-codes and Q-codesCMS has ended, newest first. Retired codes can’t be reported for dates of service after their last valid date.
Retired in 2025
- J0172Injection, aducanumab-avwa, 2 mg
- J0190Injection, biperiden lactate, per 5 mg
- J0200Injection, alatrofloxacin mesylate, 100 mg
- J0205Injection, alglucerase, per 10 units
- J0215Injection, alefacept, 0.5 mg
- J0288Injection, amphotericin b cholesteryl sulfate complex, 10 mg
- J0350Injection, anistreplase, per 30 units
- J0365Injection, aprotonin, 10,000 kiu
- J0380Injection, metaraminol bitartrate, per 10 mg
- J0395Injection, arbutamine hcl, 1 mg
- J0710Injection, cephapirin sodium, up to 1 gm
- J0715Injection, ceftizoxime sodium, per 500 mg
- J0795Injection, corticorelin ovine triflutate, 1 microgram
- J0889Daprodustat, oral, 1 mg, (for esrd on dialysis)
- J1267Injection, doripenem, 10 mg
- J1330Injection, ergonovine maleate, up to 0.2 mg
- J1443Injection, ferric pyrophosphate citrate solution (triferic), 0.1 mg of iron
- J1444Injection, ferric pyrophosphate citrate powder, 0.1 mg of iron
- J1445Injection, ferric pyrophosphate citrate solution (triferic avnu), 0.1 mg of iron
- J1452Injection, fomivirsen sodium, intraocular, 1.65 mg
- J1457Injection, gallium nitrate, 1 mg
- J1562Injection, immune globulin (vivaglobin), 100 mg
- J1620Injection, gonadorelin hydrochloride, per 100 mcg
- J1655Injection, tinzaparin sodium, 1000 iu
- J1710Injection, hydrocortisone sodium phosphate, up to 50 mg
- J1945Injection, lepirudin, 50 mg
- J2504Injection, pegademase bovine, 25 iu
- J2513Injection, pentastarch, 10% solution, 100 ml
- J2910Injection, aurothioglucose, up to 50 mg
- J2940Injection, somatrem, 1 mg
- J2995Injection, streptokinase, per 250,000 iu
- J3280Injection, thiethylperazine maleate, up to 10 mg
- J3305Injection, trimetrexate glucuronate, per 25 mg
- J3310Injection, perphenazine, up to 5 mg
- J3320Injection, spectinomycin dihydrochloride, up to 2 gm
- J3355Injection, urofollitropin, 75 iu
- J3364Injection, urokinase, 5000 iu vial
- J3365Injection, iv, urokinase, 250,000 i.u. vial
- J3400Injection, triflupromazine hcl, up to 20 mg
- J7309Methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gram
- J7310Ganciclovir, 4.5 mg, long-acting implant
- J7505Muromonab-cd3, parenteral, 5 mg
- J7513Daclizumab, parenteral, 25 mg
- J8562Fludarabine phosphate, oral, 10 mg
- J8650Nabilone, oral, 1 mg
- J9019Injection, asparaginase (erwinaze), 1,000 iu
- J9020Injection, asparaginase, not otherwise specified, 10,000 units
- J9098Injection, cytarabine liposome, 10 mg
- J9151Injection, daunorubicin citrate, liposomal formulation, 10 mg
- J9165Injection, diethylstilbestrol diphosphate, 250 mg
- J9212Injection, interferon alfacon-1, recombinant, 1 microgram
- J9270Injection, plicamycin, 2.5 mg
- Q0174Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
- Q2017Injection, teniposide, 50 mg
- Q5109Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- J2150Injection, mannitol, 25% in 50 ml
- J2503Injection, pegaptanib sodium, 0.3 mg
- J0171Injection, adrenalin, epinephrine, 0.1 mg
- J0173Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg
- J2310Injection, naloxone hydrochloride, per 1 mg
- J2311Injection, naloxone hydrochloride (zimhi), 1 mg
- J3370Injection, vancomycin hcl, 500 mg
- J3371Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg
- J3372Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg
- J9340Injection, thiotepa, 15 mg
- J1094Injection, dexamethasone acetate, 1 mg
- J1300Injection, eculizumab, 10 mg
- J1810Injection, droperidol and fentanyl citrate, up to 2 ml ampule
- J1890Injection, cephalothin sodium, up to 1 gram
- J1940Injection, furosemide, up to 20 mg
- J9037Injection, belantamab mafodotin-blmf, 0.5 mg
- J9247Injection, melphalan flufenamide, 1mg
- Q5139Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
Retired in 2024
- J0135Injection, adalimumab, 20 mg
- J2796Injection, romiplostim, 10 micrograms
- J2806Injection, sincalide (maia), not therapeutically equivalent to j2805, 5 micrograms
- J9058Injection, bendamustine hydrochloride (apotex), 1 mg
- J9059Injection, bendamustine hydrochloride (baxter), 1 mg
- J9259Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg
- Q5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
- Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
- Q0220Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg
- Q0221Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
- Q0222Injection, bebtelovimab, 175 mg
- Q0240Injection, casirivimab and imdevimab, 600 mg
- Q0243Injection, casirivimab and imdevimab, 2400 mg
- Q0244Injection, casirivimab and imdevimab, 1200 mg
- Q0247Injection, sotrovimab, 500 mg
- J1170Injection, hydromorphone, up to 4 mg
- J2001Injection, lidocaine hcl for intravenous infusion, 10 mg
- J8520Capecitabine, oral, 150 mg
- J8521Capecitabine, oral, 500 mg
- J9258Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg
- J2780Injection, ranitidine hydrochloride, 25 mg
- J9371Injection, vincristine sulfate liposome, 1 mg
- J0576Injection, buprenorphine extended-release (brixadi), 1 mg
- J1020Injection, methylprednisolone acetate, 20 mg
- J1030Injection, methylprednisolone acetate, 40 mg
- J1040Injection, methylprednisolone acetate, 80 mg
- J1840Injection, kanamycin sulfate, up to 500 mg
- J1850Injection, kanamycin sulfate, up to 75 mg
- J2920Injection, methylprednisolone sodium succinate, up to 40 mg
- J2930Injection, methylprednisolone sodium succinate, up to 125 mg
- J9070Cyclophosphamide, 100 mg
- J9250Methotrexate sodium, 5 mg
Retired in 2023
- J9160Injection, denileukin diftitox, 300 micrograms
- Q0245Injection, bamlanivimab and etesevimab, 2100 mg
- J0800Injection, corticotropin, up to 40 units
- J2370Injection, phenylephrine hcl, up to 1 ml
- J0610Injection, calcium gluconate (fresenius kabi), per 10 ml
- J0611Injection, calcium gluconate (wg critical care), per 10 ml
Retired in 2022
Retired in 2021
- J2505Injection, pegfilgrastim, 6 mg
- J0693Injection, cefiderocol, 5 mg
- J7303Contraceptive supply, hormone containing vaginal ring, each
- J9315Injection, romidepsin, 1 mg
- Q0239Injection, bamlanivimab-xxxx, 700 mg
- J7333Hyaluronan or derivative, visco-3, for intra-articular injection, per dose
- J7401Mometasone furoate sinus implant, 10 micrograms
Retired in 2020
Retired in 2018
Retired in 2017
Retired in 2016
Retired in 2015
- J0886Injection, epoetin alfa, 1000 units (for esrd on dialysis)
- J1446Injection, tbo-filgrastim, 5 micrograms
- J7302Levonorgestrel-releasing intrauterine contraceptive system, 52 mg
- J7506Prednisone, oral, per 5 mg
- J9010Injection, alemtuzumab, 10 mg
- Q9975Injection, factor viii fc fusion protein (recombinant), per iu
- Q9976Injection, ferric pyrophosphate citrate solution, 0.1 mg of iron
- Q9979Injection, alemtuzumab, 1 mg
Retired in 2014
- J0150Injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
- J0151Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
- J0900Injection, testosterone enanthate and estradiol valerate, up to 1 cc
- J1060Injection, testosterone cypionate and estradiol cypionate, up to 1 ml
- J1070Injection, testosterone cypionate, up to 100 mg
- J1080Injection, testosterone cypionate, 1 cc, 200 mg
- J2271Injection, morphine sulfate, 100mg
- J2275Injection, morphine sulfate (preservative-free sterile solution), per 10 mg
- J3120Injection, testosterone enanthate, up to 100 mg
- J3130Injection, testosterone enanthate, up to 200 mg
- J3140Injection, testosterone suspension, up to 50 mg
- J3150Injection, testosterone propionate, up to 100 mg
- J7335Capsaicin 8% patch, per 10 square centimeters
- J9265Injection, paclitaxel, 30 mg
- Q9970Injection, ferric carboxymaltose, 1mg
- Q9972Injection, epoetin beta, 1 microgram, (for esrd on dialysis)
- Q9973Injection, epoetin beta, 1 microgram, (non-esrd use)
- Q9974Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg